10x Genomics, Inc. - TXG STOCK NEWS

10x Genomics (TXG) announced the commercial launch of BEAM (Barcode Enabled Antigen Mapping), a new solution aimed at accelerating antibody and T-cell receptor discovery. Built on the Chromium Single Cell Immune Profiling technology, BEAM allows comprehensive antigen screening, significantly improving therapeutic discovery timelines. The workflow is optimized for efficiency, taking only a week and promising robust data output. This marks the sixth major product launch from 10x Genomics in 2022, demonstrating the strength of its R&D pipeline, with shipping expected to begin in December 2022.

10x Genomics (Nasdaq: TXG) reported its third quarter 2022 financial results, revealing a revenue of $131.1 million, up 5% year-over-year and 14% quarter-over-quarter. The gross margin decreased to 77% from 80% due to increased costs and changes in product mix. Operating expenses surged 21% to $140.7 million, contributing to a significant operating loss of $40 million compared to $15.9 million last year. The net loss reached $41.9 million, widening from $17.2 million. 10x Genomics maintains its 2022 revenue guidance of $500 million to $520 million.

10x Genomics (Nasdaq: TXG) will host an Investor Day on December 8, 2022, at its headquarters in Pleasanton, CA, starting at 9:00 a.m. PT. The event will feature presentations from the leadership team and a Q&A session.

The live webcast will be accessible via the company's website, with an archive available for 45 days post-event. In-person attendance is limited and by invitation only. 10x Genomics specializes in life science technology, providing integrated solutions for biological analysis, with a strong presence in top research institutions worldwide.

10x Genomics (Nasdaq: TXG) will announce its third quarter 2022 financial results after market close on November 2, 2022. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, business developments, and future outlook. Investors can access the live audio on the company's website, with playback available for at least 45 days post-event. 10x Genomics provides advanced life science technology solutions for analyzing biological systems, with strong adoption among leading global research institutions and pharmaceutical companies.

10x Genomics (Nasdaq: TXG) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 10:35 a.m. Eastern Time. The company will engage in a fireside chat, with a live and archived webcast available on its investors' webpage. 10x Genomics, a life sciences technology leader, focuses on products that enhance understanding of biological systems. Their solutions are widely adopted by top global research institutions and pharmaceutical companies, backed by over 1,500 patents and citations in over 3,800 research papers.

10x Genomics (NASDAQ: TXG) reported a 1% decrease in revenue for Q2 2022, totaling $114.6 million, down from $115.8 million in Q2 2021. Factors included decreased demand from China, logistics issues in Europe, and foreign exchange challenges. The gross margin fell to 76%, significantly down from 96% in the previous year. Operating expenses rose 24% to $150 million, with an operating loss of $63.1 million compared to $10.3 million last year. The company revised its 2022 revenue guidance to $500-$520 million, reflecting 2%-6% growth.

10x Genomics, Inc. (NASDAQ: TXG) announced its participation in the UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California, scheduled for August 11, 2022, at 9:00 a.m. PT. The company's management will engage in a fireside chat, which will also be accessible via webcast on the company's investor website. 10x Genomics focuses on life sciences technology, offering advanced biological analysis tools and has over 1,500 patents. Their products are widely used by leading researchers and pharmaceutical companies globally.

10x Genomics, Inc. (Nasdaq: TXG) has appointed Jim Wilbur, Ph.D., as the new Chief Commercial Officer, effective July 27, 2022. With nearly 30 years of experience in building businesses and leading commercial teams, Wilbur will enhance the company’s commercial strategy and execution. Previously at Meso Scale Discovery, he led the commercial functions and achieved significant growth. Wilbur is optimistic about 10x's potential in single cell and spatial biology and aims to drive a culture of commercial excellence.

10x Genomics, Inc. (Nasdaq: TXG) announced preliminary revenue of approximately $114.5 million for Q2 2022, marking a 1% decrease year-over-year. Geographic revenue breakdown shows Americas at $70.9 million (+8%), EMEA at $25.6 million (-11%), and APAC at $18.1 million (-15%). CEO Serge Saxonov noted that results fell short of expectations but expressed confidence in future growth. The company will provide a full financial outlook on August 8, 2022, during their earnings call.